Net Cash Provided by (Used in) Operating Activities in USD of Ambrx Biopharma Cayman, Inc. from 2019 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Ambrx Biopharma Cayman, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities history and change rate from 2019 to Q1 2023.
  • Ambrx Biopharma Cayman, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2023 was $12,967,000, a 49% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $68,675,000, a 54% decline from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was $44,640,000, a 117% decline from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2020 was $20,576,000, a 644% decline from 2019.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $12,967,000 +$12,697,000 +49% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q1 2022 $25,664,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1

Ambrx Biopharma Cayman, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $68,675,000 -$24,035,000 -54% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023 2022 FY
2021 $44,640,000 -$24,064,000 -117% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $20,576,000 -$17,811,000 -644% 01 Jan 2020 31 Dec 2020 20-F 26 Apr 2022 2021 FY
2019 $2,765,000 01 Jan 2019 31 Dec 2019 20-F 26 Apr 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.